Cannabigerol (CBG) is a non-psychoactive cannabinoid found in the Cannabis genus of plants. Cannabigerol is found in higher concentrations in hemp rather than in varieties of Cannabis cultivated for high THC content and their corresponding psychoactive properties.
Cannabigerol has been found to act as a high affinity α2-adrenergic receptor agonist, moderate affinity 5-HT1A receptor antagonist, and low affinity CB1 receptor antagonist. It also binds to the CB2 receptor, but whether it acts as an agonist or antagonist at this site is unknown.
It has two E/Z isomers.
Cannabigerol has been shown to relieve interocular pressure, which may be of benefit in the treatment of glaucoma. It can also be used to treat inflammatory bowel disease.
CBG is not scheduled by Convention on Psychotropic Substances.
CBG is not scheduled at the federal level in the United States.